A Case of Kasabach-Merritt Syndrome Successfully Treated with Interferon-alpha 2b and Propranolol / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
;
: 161-166, 2015.
Article
in English
| WPRIM
| ID: wpr-788551
ABSTRACT
Kasabach-Merritt syndrome (KMS) is a rare, life-threatening disease characterized by rapidly enlarging hemangioma and consumptive coagulopathy. We report a case of KMS in a 28-day-old female neonate with a huge mixed type hemangioma on her right thigh with muscle involvement and severe venous engorgement, who was refractory to prednisone therapy, but was successfully managed with the interferon (IFN)-alpha 2b and propranolol combination therapy. By the third week of IFN-alpha 2b treatment, hematological parameters had normalized and the hemangioma size had dramatically decreased, and after 5 months of the treatment, complete resolution was observed visually. We also measured serum levels of cytokines including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), monocyte chemoattractant protein-1 (MCP-1) and platelet-derived growth factor-BB (PDGF-BB), at diagnosis and serially during treatment but the levels did not correlate with the clinical response. The patient has not shown relapse after 20 months of follow up.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Propranolol
/
Recurrence
/
Thigh
/
Prednisone
/
Follow-Up Studies
/
Cytokines
/
Fibroblast Growth Factor 2
/
Interferons
/
Interferon-alpha
/
Chemokine CCL2
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
/
Infant, Newborn
Language:
English
Journal:
Clinical Pediatric Hematology-Oncology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS